A phase II study of recombinant interferon-beta (r-hIFN-β 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma

British Journal of Cancer

Volumn 75, Issue 3, 1997, Pages 423-426

  Joffe, J K ^a,d   Perren, T J ^a   Bradley, C ^b   Primrose, J ^c   Hallam, S ^a   Ward, U ^a   Illingworth, J M ^e   Selby, P J ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b BRADFORD ROYAL INFIRMARY   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d HUDDERSFIELD ROYAL INFIRMARY   (United Kingdom)

^e Serono International SA   (Switzerland)

Author keywords

5 fluorouracil; Chemotherapy; Colorectal carcinoma; Interferon beta

Indexed keywords

FLUOROURACIL; RECOMBINANT BETA INTERFERON;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONFUSION; DIARRHEA; ERYTHEMA; EYE DISEASE; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEPSIS; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0031035304     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.69     Document Type: Article

References (26)

1. Burden EC, Hogan TF and Voelkel JG (1982) Comparative antiproliferative activity in vivo of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res 42: 4989-4953
2. Corfu-A Study Group (1995) Phase III randomised study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13: 921-928
3. de Grado WF, Wasserman ZR and Chowdry V (1982) Sequence and structural homologies among type I and type II interferons. Nature 300: 379-381
4. Dufour P, Husseini F, Dreyfus B, Cure H, Olivier JP, Dumas E, Prevot G, Martin C, Duclos B, Thill L, Audhuy B and Oberling F (1994) Randomised study of 5-fluorouracil (5-FU) verses 5-FU plus alpha-2 A interferon (IFN) as treatment for metastatic colorectal carcinoma (MCRC) (abstract 0220). Ann Oncol 5 (suppl. 8): 44
5. Findlay MPN, Cunningham D, Hill ME, Ellis P, Young H, Hickish T, Hanrahan A, Watson M, Norman A, Evans C, Flower M and Ott K (1994) Protracted venous infusion of 5-florouracil +/- interferon-α 2b (Intron-A) in patients with advanced colorectal cancer: results of a phase III trial and a parallel study measuring tumour fluorodeoxyglucose with positron emission tomography (abstract 559). Proc ASCO 13
6. Graf W, Pahlman L, Bergstrom R and Glimelius B (1994) The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 70: 559-563
7. Hill M, Norman A, Cunningham D, Findlay M, Nicolson V, Hill A, Iveson A, Evans C, Joffe J, Nicolson M and Hickish T (1995) Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 13: 1297-1302
8. Kase S, Kubota T, Watanabe M, Furukawa T, Tanino H, Ishibiki K, Teramoto T and Kitajima M (1993) Interferon beta increases antitumour activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo. Anticancer Res 13: 369-373
9. Kemeny N and Younes A (1992) Alfa-2A interferon and 5-fluorouracil for advanced colorectal carcinoma: The Memorial Sloan-Kettering experience. Semin Oncol 19 (suppl.3): 171-175
10. Kemeny N, Younes A, Seiter K, Kelson D, Sammarco P, Adams L, Derby S, Murray P and Houston C (1990)) Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer 66: 2470-2475
11. Lillis PK, Brown TD, Beougher K, et al (1987) Phase II trial of recombinant beta interferon in advanced colorectal cancer. Cancer Treat Rep 71: 965-967
12. Nordic Gastrointestinal Tumour Adjuvant Therapy Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomised trial. J Clin Oncol 10: 904-911
13. Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B, DuBrow R, Campos L, Quaraishi M, Faintuch J, Abbruzzese JL, Gutterman J and Levin B (1990) Phase II study of fluorouracil and recombinant interferon alla-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 8: 2027-2031
14. Pittman K, Perren T, Ward U, Primrose J, Stevin M, Patel N and Selby P (1993) Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon. Ann Oncol 4: 515-516
15. Ruzicka FJ, Jach ME and Borden EC (1987) Binding of recombinant-produced interferon-beta ser to human lymphoblastoid cells. J Biol Chem 262: 16142-16149
16. Scheithauer W, Rosen H, Kornek G-V, Sebesta C and Depisch D (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306: 752-755
17. Seymour MT, Slevin M, Cunningham D, Kerr D, James R, Lederman J, Perren T, McAdam W, Duffy A, Stenning S and Taylor I (1994) A randomised trial to assess the addition of inteferon-α2a (IFN-α). to 5-fluorourucil and leucovorin in advanced colorectal cancer (abstract P237). Ann Oncol 5 (suppl. 8): 48
18. Triozzi PL, Kenney P, Young D, et al (1987) Open label phase II trial of recombinant beta interferon in patients with colorectal cancer. Cancer Treat Rep 71: 983-984
19. Villar A, Massuti B, Candel M, et al. (1995) Survival benefit from adding interferon-β (Frone) to a fluorouracil regimen in advanced colorectal cancer (CRC) (abstract 579). Proc ASCO 14: 225
20. Wadler S and Schwartz KL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Rev 50: 3473-3486
21. Wadler S and Wiernick PH (1990) Clinical update on the role of flourouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Semin Oncol 17 (suppl.1): 16-21
22. Wadler S, Schwartz LL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V and Wiernik PH (1989) Fluorouracil and recombinant alfa-2a-interferon: an active regimen against colorectal carcinoma. J Clin Oncol 7: 1769-1775
23. Wadler S, Lemberskey B, Atkins M, Kirkwood J and Petrelli N (1991) Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Laslern Cooperative Oncology Group Study. J Clin Oncol 9: 1806-1810
24. Weh HJ, Platz D, Braumann D, Buggisch P, Eckardt N, Schmiegel WH, Drescher S, Kleeberg UR, Mullerleile U, Crone-Munzbrock W, Hoffmann R, Muller P, Klapdor R, Pompecki R, Erdmann H, Reichel L, Jungbluth M, Hoffmann L, Mainzer K and Hossfeld DK (1992) Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinoma. Eur J Cancer 28A: 1820-1823
25. Wong VL, Rieman DJ, Aronson L, Dallon BJ, Grieg R and Anzano MA (1989) Growth inhibitory activity of interferon-beta against human colorectal carcinoma cell lines. Int J Cancer 43: 526-530
26. York M, Greco FA, Figlin RA, Einborn L, Man T, Cockey L, Mott D and Light SE (1993) A randomised phase III trial comparing 5-FU with or without interferon-α2A for advanced colorectal cancer (abstract 590). Proc ASCO 12: 200